ALDER BIOPHARMACEUTICALS INC's ticker is ALDR and the CUSIP is 014339105. A total of 145 filers reported holding ALDER BIOPHARMACEUTICALS INC in Q1 2017. The put-call ratio across all filers is 1.10 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $5,240,000 | +364.1% | 445,200 | +438.3% | 0.01% | +150.0% |
| Q1 2019 | $1,129,000 | +72.1% | 82,700 | +29.2% | 0.00% | +33.3% |
| Q4 2018 | $656,000 | +110.9% | 64,000 | +224.9% | 0.00% | +200.0% |
| Q2 2018 | $311,000 | -95.6% | 19,700 | -96.5% | 0.00% | -96.4% |
| Q1 2018 | $7,085,000 | -43.1% | 557,909 | -48.7% | 0.03% | -42.9% |
| Q4 2017 | $12,448,000 | +2.4% | 1,087,209 | +9.6% | 0.05% | -5.8% |
| Q3 2017 | $12,153,000 | +220.8% | 992,083 | +199.9% | 0.05% | +205.9% |
| Q2 2017 | $3,788,000 | -46.9% | 330,830 | -3.6% | 0.02% | -46.9% |
| Q1 2017 | $7,138,000 | +28.6% | 343,193 | +28.7% | 0.03% | +23.1% |
| Q4 2016 | $5,549,000 | -35.3% | 266,758 | +1.9% | 0.03% | -31.6% |
| Q3 2016 | $8,576,000 | +19.8% | 261,690 | -8.7% | 0.04% | +18.8% |
| Q2 2016 | $7,157,000 | +15.4% | 286,620 | +13.2% | 0.03% | +14.3% |
| Q1 2016 | $6,200,000 | -27.0% | 253,179 | -1.6% | 0.03% | -24.3% |
| Q4 2015 | $8,498,000 | +6.1% | 257,269 | +5.2% | 0.04% | +12.1% |
| Q3 2015 | $8,010,000 | -20.2% | 244,509 | +29.1% | 0.03% | -17.5% |
| Q2 2015 | $10,034,000 | – | 189,435 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 229,895 | $7,593,000 | 6.73% |
| Foresite Capital Management II, LLC | 419,997 | $13,873,000 | 4.65% |
| Cormorant Asset Management, LP | 757,475 | $25,019,000 | 2.99% |
| NEXTHERA CAPITAL LP | 60,000 | $1,982,000 | 2.81% |
| SENZAR ASSET MANAGEMENT, LLC | 557,170 | $18,403,325,000 | 2.05% |
| Parametrica Management Ltd | 9,360 | $309,000 | 2.04% |
| Partner Investment Management, L.P. | 36,756 | $1,214,000 | 1.99% |
| PFM Health Sciences, LP | 1,890,030 | $62,428,000 | 1.90% |
| PYRRHO CAPITAL MANAGEMENT, LP | 63,000 | $2,081,000 | 1.40% |
| BB BIOTECH AG | 1,510,150 | $49,880,000 | 1.40% |